NCT05079633View on ClinicalTrials.gov

A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults

PHASE4CompletedINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

October 8, 2021

Study Completion Date

January 10, 2023

Conditions

Covid19 Vaccine

Interventions

BIOLOGICAL

Homologous boost schedule

1st dose mRNA 1273 , 2nd dose mRNA 1273

BIOLOGICAL

Heterologous boost schedule

1st dose mRNA 1273 , 2nd dose MVC COV1901

Trial Locations (1)

Unknown

National Taiwan University Hospital, Taipei

All Listed Sponsors

lead

National Taiwan University Hospital

OTHER

NCT05079633 - A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults | Biotech Hunter | Biotech Hunter